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Abstract
The 2014 public health crisis in Guinea, Liberia, and Sierra Leone has brought Ebola Viral
Disease (EVD) to everyone’s attention. Discovered in 1976, this deadly disease
infrequently struck in remote areas of Africa. This article will critically review the literature
and describe the pathobiology, transmission, signs and symptoms, diagnosis, treatment,
and prevention of EVDwhich, was predicted by the Centers for Disease Control to
potentially infect 1.4 million persons in Liberia and Sierra Leone by January 2015
(“Questions and Answers”, 2014). Thankfully this worst case scenario did not occur and
we may be experiencing natural burn out of the outbreak along with the results of
aggressive education and supportive treatment as in Sierra Leone. There is no established
treatment for EVD despite successes in non-human models. The WHO endorsed
Convalescent Blood Products (“Potential for use of…,” 2014) after it showed promise in
Democratic Republic of Congo. In 2014, American Ebola patients recovered after
receiving Convalescent Serum Therapy (CST) with experimental therapies like Zmapp,
TKM-Ebola, and Brincidofovir. We may have missed the window of opportunity to
establish the efficacy of these potential therapies, which may have unprecedented
implications for health status, healthcare infrastructure development in the future, and the
economic viability of the sub-region for decades to come. Additionally, an endemic area
will pose a threat to the rest of the world as a potential incubator/exporter of this dangerous
viral illness.
Keywords: Ebola virus disease, convalescent serum therapy, convalescent blood products,
rapid advance treatment, super-spreaders, cultural burial practices, personal protective
equipment, survivability, susceptibility, hemorrhagic fever, Ebola prevention and
treatment implementation plan, Hastings Ebola Cocktail.
Introduction
Ebola Virus Disease (EVD) is a viral hemorrhagic fever caused by the Ebola virus
(EBOV) (Breman et al., 1978). During the latest unprecedented outbreak in Sierra Leone,
Liberia, and Guinea, initial mortality rates reached between 55 and 70%, with no wellestablished treatments yet found for EVD. While numerous in vitro systems and animal models
have led to effective treatments in non-human primate models, no in vitro systems have been
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systematically tested in humans nor are expected to be available to impact the current epidemic
(Ansari, 2014).
The main purpose of this review is to present an argument for the usefulness of
Convalescent Serum Therapy (CST) as a Rapid Advance Treatment (RAT), both to reduce
mortality rates and also to gain the psychological advantage as more transmission determent
strategies are deployed beyond the standard Quarantine, Isolation, and Case Finding public
health tools. We will review CST and compare it to other experimental and routine therapies that
were touted at the start of the epidemic in West Africa about 12 months ago (2014) but have
since been unavailable to diminish morbidity and mortality (Ansari, 2014).
We will start by reviewing EVD demographics, biology, pathophysiology, clinical
presentation, diagnosis, and predilection for the immune system. The review will also identify
individuals who are most at risk, EVD’s transmission mechanisms, and available methods for
prevention of transmission. The article will also discuss benefits of surveillance, early warning,
the fear of endemic EVD, and how these factors influence the socio-developmental trajectory of
the West African sub-region.
Ebola Virus Disease and Human Development
The West African Ebola epidemic’s short-term socioeconomic impact and long-term
effect on human development will take some time to fully realize. It is clear, however, based on
the scale of the current outbreak, that the economies of the most affected countries, Sierra Leone,
Liberia, and Guinea, will bear the aftermath of this epidemic for a long time to come. The World
Bank Group recently completed forecasts of economic impacts on the three most affected
countries and on the West African region (2014). These conservative forecasts focus on core
economic activity but do not account for long-term impacts generated by mortality, failure to
treat other health conditions due to aversion behavior and lack of supply capacity, school
closings and dropouts, and other shocks to livelihood. Nonetheless, in the short term, this
forecast estimates the forgone output for these three countries to be approximately US$359
million in 2013 prices: 2.1 percentage points (pp) drop in gross domestic product (GDP) for
Guinea, 3.4 pp drop in GDP for Liberia, and 3.3 pp drop in GDP for Sierra Leone. These very
significant numbers represent a drop of anywhere from a third to half of economic growth rates
for these countries (World Bank Group, 2015).
The long-term outlook is assumed since it is unclear whether the epidemic can be
completely extinguished (the “zero cases” scenario) or whether it will ultimately stabilize in an
endemic low-intensity mode. These two scenarios bear very dire prospects for long-term
development in the affected countries. With a combined GDP of $13.1 billion in 2013, the worstcase impact predictions forecast over $9 billion in loss, even if the disease is rapidly contained
(Holtz, 2014). According to the World Bank 2014 Ebola economic report, which considers both
“low Ebola” and “high Ebola” scenarios, the long-term impact on development could be
crippling to countries already devastated by war and entrenched poverty.
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Ultimately the effect of this epidemic on quality of life is just as important as the direct
effects on the economies of these countries and of the region. The economic effects, whether
bearing directly on economic activity or indirectly on development, will negatively manifest in
human quality of life, including the people’s health status. By focusing on the human impact, we
can better galvanize action that is relevant both for Ebola outbreaks as well as post-Ebola
recovery. Therapies that cost-effectively improve survivability, such as CST, are particularly
important in this respect. In the post-Ebola era, it will be of particular importance to establish
empowering grassroots community health systems on a community-by-community basis.
Etiology of Ebola Virus Disease
EVD is a viral hemorrhagic fever that can be abrupt, severe, and fatal in humans. It also
infects non-human primates like monkeys, gorillas, and chimpanzees. The Ebola virus is part of
the family Filovirida and genus Ebolavirus. Its molecular structure is that of an enveloped,
negative sense Ribonucleic acid (RNA), 1200 nanometers long, that codes for several proteins
that function in its life cycle and aid in its pathogenesis (Ansari, 2014). EVD was first isolated
during an outbreak in 1976 in the Democratic Republic of Congo (DRC), near the Ebola River.
Outbreaks have been relatively sporadic and short-lived, killing virtually all who are infected and
burning out quickly. In fact, there was a minor outbreak in DRC concurrent with, but separate
and distinct from, the West African outbreak (Maganga et al., 2014).
To date, five subspecies of Ebola virus have been described: the Zaire, Sudan, Tai Forest,
Bundibugyo, and Reston viruses. Reston has not caused clinical disease in humans and was
isolated in infected cynomolgous monkeys from the Philippines (Ansari, 2014). Ebola’s natural
reservoir is not yet known with any certainty. It is thought to reside in the fruit bat or some form
of zoonotic illness (Leroy et al., 2005). This raises the interesting question of whether EVD is
transmitted by wild game, known locally as “bush meat,” that is consumed in some of the
affected areas (“Facts about Bushmeat and Ebola,” 2014).
It is not yet known how the EVD arrived in West Africa. The most common hypothesis is
that patient zero, a young boy in Guinea who has since died along with his entire family,
contracted the virus through direct contact with an infected animal (Funk & Piot, 2014).
However, this hypothesis has not been historically substantiated. EVD invades human tissues
and cells by entering through breaks in the skin and mucus membranes when a person is exposed
to body fluids from an infected individual. Person-to-person transmission of EVD occurs via
contact with an infected person’s blood or secretions, including urine, saliva, feces, vomitus, and
semen. Also, exposure to objects like needles that are contaminated with infected secretions can
cause transmission by needle-sticks, whether inadvertent as in the case of healthcare and
laboratory workers, or by needle and syringe re-use as the result of improper sterilization
techniques (Breman & Piot, 1976). Poor barrier protective practices in health care settings can
also result in EVD contraction. This includes not adequately wearing Personal Protective
Equipment (PPE) like masks, gowns, or gloves, and improper disposal of contaminated
instruments.
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Although EVD’s pathobiology is not well understood, it is known that the virus disables
the immune system, “allowing for the uncontrolled replication of Ebolaviruses” (Ansari, 2015).
The initial symptoms presentation complex may include fever (>38.6 C or 101.5 F), headache,
joint aches, muscle aches, weakness, diarrhea, vomiting, abdominal pain, and anorexia. In fact,
this initial symptom complex is almost identical in two geographically distinct cohorts of
patients, one in Hastings, Sierra Leone who presented with fatigue, anorexia, fever, vomiting,
nausea, diarrhea, muscle pains, joint pains, and headaches (Ansumana et al., 2014), and one in
Boende Town, DRC who presented with fatigue, anorexia, fever, vomiting, nausea, diarrhea,
muscle pains, and headaches (Maganga et al., 2014).
While the extremes of the incubation period last from two to twenty-one days, a typical
incubation period lasts eight to ten days. Early symptoms are usually the ones typified above, but
can also include unexplained bleeding or bruising, rash, conjunctival injection, hiccups, cough,
sore throat, chest pain, dyspnea, dysphagia, and life-threatening hemorrhage. Many of these also
tend to be late complications. Early diagnosis is difficult because symptoms are non-specific,
which presents a significant challenge, as potentially life-saving hospital supportive treatment
does not usually occur until later in disease progression. Best practices include immediate
isolation of patients who present early symptoms and are at risk for EVD and notification of
public health professionals for immediate point of care testing in the field (Ebola Diagnosis,
2015). Early supportive treatment such as treatment with Intravenous fluids (IVF), maintenance
of oxygenation and blood pressure, and treatment of other infections, increases the chance of
survival as has been demonstrated during this epidemic (Ansumana, et al., 2015).
Culturally distinct burial practices that include touching the remains of a loved one may
have contributed significantly to spread of the disease and have emerged as a distinct risk factor
for disease transmission and increased prevalence in affected communities (Ebola Situation
Report, 2015). Both the Central African and West African regions share this distinct risk factor
for transmission of the virus (Maganga et al., 2014). It has been reported that 60% of EVD
transmission cases in Guinea were linked to funerals that involve close contact with corpses
(Chan, 2014). More medical anthropology research will need to be undertaken to understand the
actual mechanism and implications of this hypothesis. There is no current understanding or
general agreement on what these so-called cultural burial practices involve.
As expected, family, friends, health care personnel, and aides are at greatest risk as they
perform direct patient care and clean up infected bodily fluids. Other stakeholders most
concerned about the effects of this disease include people living in epidemic areas, international
staff working and living in affected areas, airline personnel, travelers, staff of Governmental and
Non-Governmental Agencies (NGOs) such as the Red Cross and Médecins Sans Frontières
(MSF), and international agencies like the United Nations and the World Health Organization
(WHO). Current thinking and published literature on susceptibility and survivability are
primarily based in the study of basic science on molecular genetic analysis of so-called
transcriptomes and kinomes (Ansari, 2014). These are genetic epitopes that are thought to
naturally expose Ebola victims to either improved or weakened survival rates There is anecdotal
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indication that sociopolitical and community factors, including but not limited to poor
community health infrastructure and poor governance that cannot completely prevent at-risk
burial practices, also expose certain groups of people to greater risk (Ebola Situation Report,
2015).
Convalescent Serum Therapy in Ebola Patient Management
Given the dearth of therapies available to treat this devastating viral illness, the World
Health Organization (WHO) has released a position statement supporting the use of Convalescent
Blood products (CBP) to treat EVD in this outbreak (Blood Regulators Network, 2014). There is
evidence to suggest a significant mortality benefit with the use of convalescent whole blood, which
was first described in the Kikwit, DRC outbreak in 1995, when a seven out of eight survival benefit
was demonstrated in a small study. However, the epidemic ended before a well-designed clinical
trial could begin (Muyembe-Tafum et al., 1999). Convalescent serum is defined as a blood product
devoid of red blood cells and clotting factors that contains Immunoglobulins IgM and IgG obtained
from someone who has recuperated from a particular infection, in this case EVD. Convalescent
serum therapy is the use of this serum to treat a person with the same disease. Several studies on
CST treatment methodology are well established in the treatment of other viral hemorrhagic fevers
such as Junin virus hemorrhagic fever in Argentina (Erina et al., 2008; Maiztegui, & De Damilano,
1979). Lassa passive immune therapy was also used successfully in five well-documented cases
in Nigeria in 1970, in which four out of five patients recovered and only one was considered to
have had an adverse reaction (Monath & Casals, 1975). Pooled convalescent serum therapy was
implemented in the treatment of Lassa fever in Lofa County, Liberia in 1986; early data showed
some benefit but unfortunately the trial was terminated prematurely due to an armed insurgency at
the time (Frame, 1990). In addition, other small cohorts of patients treated in other studies using
convalescent serum showed improvement that was attributed to the serum (Frame & Verbrugge,
1984; Leifer et al., 1970). According to media reports, convalescent blood product (CBP) has been
used in 11 recorded cases in the Western hemisphere during the current EVD outbreak (Yahoo
Finance, 2014). All of these patients recovered without adverse outcomes in the short term.
However, they also received other experimental therapies alongside CBP like Zmapp, TKMEbola, and Brincidofovir; thus the dispositive factor in their recovery remains unclear.
Given these positive examples of CBP use, we will perform a comparative review of the
use of CBP versus other experimental and routine therapies, and then comment on the potential
usefulness of CBP in future potential epidemics in the region and how CBP might impact
healthcare infrastructure development and economic independence and viability for decades to
come. Multiple candidates have been proposed and are under examination for the treatment of
Ebola. These candidates fall largely into the categories of blood therapies, drug therapies, and
vaccines (Table 1). Unfortunately, none of these candidate therapies have been deployed in the
affected countries to the extent necessary to make a difference in the current epidemic. No doubt
the reasons for this unfortunate situation will be under debate in the literature and lay press for
years to come.
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As Table 1 illustrates, blood therapies appear to be the most accessible, affordable, and
easy to deploy by the affected countries independent of external aid. In contrast, drug therapies
and vaccines are out of reach for these resource-strapped countries, at least for the near future.
Table 1

Treatment Options for Ebola Virus Disease (EVD)
Treatment Type

Blood
Therapies

Drug
Therapies

Vaccines

Other: "Hastings
Ebola Cocktail"
(HEC)

Overview
Blood trials were successfully used in the Kikwit, DRC outbreak with
reduction of case fatality rate (CFR) from 80% to 12.5%, but only in 8
patients. Limited whole blood trials in Sierra Leone also anecdotally
reported 12.5% CFR with whole blood use (Samba A., 2015).
Serum treatments are standard in Argentina for treatment of the Junin
virus or Argentine hemorrhagic fever (AHF), reducing mortality rates
to less than 1% when administered within a week of infection (Singh &
Ruzek, 2014).
 Natural and affordable resource, thus less costly to the
community
 Reduced complexity in donor-to-recipient compatibility and
donors can donate up to twice each week
 Requires considerable logistical expertise to avoid mislabeling
and mismatching and to ensure proper storage
Drug therapies include the commonly known drug Zmapp, which was
used to treat missionaries Kent Brantly and Nancy Writebol. Other
similar drugs include Zmab and Favipiravir.
 High research and production costs may not be affordable for
most in poor countries.
 Require cold storage, another challenge for these countries
These will require lots of testing before approval. Also, vaccines can be
challenging to develop when breakouts do not last long enough for
large-scale tests to be conducted.
The Hastings Ebola Cocktail was used to treat 518 patients, resulting in
24% CFR. It is a widely available and affordable cocktail of IV fluids,
antibiotics, antimalarial and nutritional supplements developed by
Sierra Leonean physicians. The protocol involves a large number of
components, thus unavailability of any constituent may undermine the
integrity and potency of the entire protocol.
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Therefore, it would be appropriate for these countries to devise an Ebola Prevention and
Treatment Implementation Plan (EPTIP) that administers blood therapies as a significant plan of
action, in conjunction with the prevention, containment, and modification of traditional burial
practices.
Due to the highly contagious nature of the disease, EVD patients, and often their family
members, are quarantined, while healthcare workers are required to wear personal protective
equipment (Brodwin, 2014). Other safety precautions include limiting the analysis of EVD
patients’ blood in clinical care non-virus isolation methods like reverse transcriptase polymerase
chain reaction (RT-PCR), antigen-capture enzyme-linked immunoabsorbent assay (ELISA), and
IgM ELISA, coupled with inactivation techniques done in mobile laboratory Point of Care Testing
(POCT) under appropriate biosafety conditions (Towner et al., 2004). Given the initial efficacy in
the use of these techniques to limit spread and thus total mortality, some experts argue that more
attention should be focused on primary prevention, early detection, and containment techniques,
over design and discovery of direct treatment modalities that are currently unavailable and may or
may not prove to be effective in the long term. While this may have been a successful strategy in
limiting total mortality of the disease during small-scale epidemics in remote Central African
regions that were already isolated (Maganga et al., 2014), it has not been systematically applied in
the West African epidemic where mortality rates have remained high (“Ebola Situation Report,”
2015). CST could significantly help in large-scale epidemics like the one in the West African subregion, where robust cross-border mixing of populations, significant urbanization, and the relative
ease of travel to urban areas make the quick isolation and quarantine of Ebola patients far more
challenging. CST, in conjunction with” an infection control method, has been recommended in the
treatment of viral hemorrhagic fevers (Ippolito et al., 2012).
Susceptibility and Survivability
Analysis of the rate of spread of the epidemic is based on an estimation of the basic
reproduction number (R0), which is the average number of secondary cases that arise when one
primary case is introduced into an uninfected population. When R0 is greater than 1, infection may
spread in the population, and the rate of spread increases with increasingly high values of R0. After
the early phase of exponential growth in case numbers, once infection has become established, the
number of people still at risk declines, so the reproduction number falls from its maximum value
of R0 to a smaller, net reproduction number, Rt. When Rt falls below 1, infection cannot be
sustained. Estimates of R0 and Rt help in evaluating the magnitude of the effort required to control
the disease, the way in which transmission rates have fluctuated through time, and the effectiveness
of control measures as they are implemented (WHO Ebola Response Team, 2014). The detailed
dynamics of Ebola, like any other infectious disease, can be investigated through the use of
Transmission Network Analysis to understand the actual mechanisms of spread. Particularly
important is the role of a small percentage of super-spreaders who account for an unusually high
percentage of disease transmissions (Smith, 2015; Yu-Hsiang et al., 2014).
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The case of one herbal healer who reportedly infected over 800—with over 360 of those
dying—illustrates the super-spreader phenomenon in the West African Ebola epidemic of 2014
(Menezes, 2014). Through analysis of these super-spreaders, a stronger, more effective response
to the disease could have been launched earlier. Analyses have revealed that unsafe burial practices
and contact with infectious individuals without adequate personal protective gear are likely
cataclysmic mechanisms of Ebola spread. The main driver of communal susceptibility, from a
policy perspective, is early reporting and effective quarantine actions, coupled with adequate
treatment by the affected communities. A related study of the efficacy of CST or Immune Serum
Treatment of Junín virus-infected marmosets was found to reduce mortality from 100% to 25%
(Avila, 1987).
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Figure 1. Epidemic Transmission Network Simulation illustrating the super-spreader phenomenon
We must integrate lessons learned from the current Ebola outbreak into a long-term
epidemic vigilance system, not only to prevent and treat Ebola, but also to treat and prevent a wide
range of communicable diseases that may emerge in the future. Above all, we want to emphasize
the role that poverty and mistrust of governmental authority have played in deterring quarantine
orders, contact tracing, and public health education. Without the voluntary community support and
compliance that we have seen during this Ebola outbreak, governmental quarantine edicts can have
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little to no influence in combating the spread of any communicable disease and such edicts may
hamper attempts to reduce susceptibility and spread. Instead, governance should create an
environment of community empowerment and shared sacrifice. A sense of common destiny
underpins community consent to the challenging measures that are necessary to protect an entire
community and ensure that future outbreaks are more easily controlled.
Analysis of the epidemic spread in West Africa also offers lessons for cross-border
epidemic control. Ebola spread from Guinea and then into Liberia and Sierra Leone has followed
a somewhat expected trend. Further spread into Nigeria, Mali, and even Senegal is unsurprising.
However, the case of Ivory Coast, a country that shares a border with Liberia’s Nimba County and
yet reports zero cases of Ebola, is quite significant (Reuters, 2014). Two likely reasons for the
difference are effective border vigilance and quick and thorough education of Ivory Coast’s
population to the risks and precautions of the Ebola threat. That said, the significance of Ivory
Coast experiencing “traditional” Ebola versus the more recent West African variety is unknown.
The devastating speed of the 2014 Ebola spread emphasizes the need for better cross-border
cooperation and vigilance in the detection and containment of likely future outbreaks. Most of the
border communities have long and deep historical ties that have been disrupted to varying degrees
by colonial borders and more recently by war. These cross-border ties must be revitalized so that
they become the basis for early warning communication systems.
Air transportation has also served as a medium for the Ebola spread, as was the case in the
transmission of Ebola into Nigeria and the United States. The challenge with air travel is the size,
complexity, and volume of the people flow and transportation network. Many airports are already
bogged down with security checks for outbound flights; additional measures for inbound flights
may prove to be too challenging to handle. Low cost, unobtrusive, and long-range temperature
monitoring devices such as those deployed in Chinese airports in the wake of the SARS outbreak
are one potential strategy for West African airports.
While it is difficult to estimate the economic impact of the Ebola outbreak on the most
affected countries, there is no doubt that impact on economic activity has been significant, with
schools closures and severe restrictions on travel and commerce. While the goal of “getting to
zero,” as the slogan of a Sierra Leone public health campaign proclaims, is ideal, realistic planning
must also consider the possibility that certain areas may control the virus but never quite eliminate
it. In the scenario of locally endemic Ebola outbreaks, societal adjustments would create a state of
permanent vigilance, which would then create severe socioeconomic impact, resulting in yet
another blow to development in these countries. The threat of an EVD flare-up would not only
affect the countries themselves, but also put all of the countries in the region, as well as outside
the region, at risk. This nightmare scenario would call for a truly international response, requiring
mutual cooperation with the affected countries and communities still in the lead. From the
consideration of survivability, there is still no definitive cure for Ebola, but CST, when serum from
survivors is transfused into current sufferers, has shown some promise.
In light of this challenging situation, CST seems to be an obvious low-cost and high impact
approach, especially for resource-strapped countries in West Africa. CST can serve as an ideal
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Rapid Advance Therapy (RAT) to quickly quell resurgent EVD in impoverished hotspots in the
future. The extraction, storage, and transfusion of serum is now a basic medical procedure that can
be safely administered practically anywhere in the world, and it does not rely on complex and
expensive technologies or pharmaceutical products. The areas in West Africa most affected by the
Ebola epidemic, particularly Sierra Leone and Liberia, are now just recovering from resource wars
that have wreaked serious havoc on the fabric of these communities.
Even without considering that many of these communities are war-torn, there are the
perennial problems of medical personnel and supply shortages and chronic underfunding of the
health systems in these countries. These facts were manifest in the ineffectual and delayed
responses to Ebola in Sierra Leone, Liberia, and Guinea. The conclusion therefore is that, in light
of the governance vacuum from the capital cities of the region, local communities are now required
to develop and implement grassroots community health programs to prioritize and use available
resources at their disposal for addressing urgent needs of the people.
CST Supply and Community Integration
The advantage of CST lies in the fact that people who have survived the disease are gifted
with curative powers. The blood plasma or serum preparation process involves spinning a tube of
fresh blood containing an anticoagulant in a centrifuge until the blood cells separate and fall to the
bottom of the tube. The blood plasma is then poured or drawn off. Plasma donation can be safely
done much more often, up to three times a week, in contrast to whole blood donation that typically
requires an eight-week period between donations.
Fortunately, CST can be designed, developed, maintained, owned, and controlled by the
poor communities independently, as opposed to the more expensive therapies that require a large
financial and technical infrastructure to deploy. In a multi-faceted grassroots Ebola response
program, it is imperative that we integrate Ebola survivors into the medical care system as
community groups to donate plasma for CST for current Ebola sufferers. In such a bottom-up
structure, the engendered reciprocity and trust will likely contribute significantly to the
strengthening of the community fabric in communities that have been plagued by entrenched
poverty, poor health, poor governance, and deep mistrust of their governments as well as the
international community.
Conclusion
We believe therefore that CST should be developed as a Rapid Advance Therapy (RAT)
to quickly quell resurgent EVD in impoverished hotspots around the world, given that CST is the
only therapy that can be designed, developed, maintained, owned, and controlled by resourcestrapped countries. This is because convalescent serum can be considered as a natural resource and
is accessible through survivor engagement and support, setup and maintenance of plasma banks,
in-depth training of personnel, and standard aggressive hospital treatment, all of which can be
accomplished within the resource structures of impoverished countries.
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Conversely, other experimental EVD therapies are still not fully tested and are too
expensive, requiring massive financial investments, capital expenditures for basic research
facilities and support infrastructure, and expertise unavailable to these impoverished countries,
leaving them dependent on wealthy international donor groups.
A strong containment strategy couples CST Rapid Advance Therapy (RAT) with early
EVD outbreak detection and prevention, which is dependent on a grassroots health infrastructure.
In the absence of this containment strategy, the future for sustained socioeconomic development
in the West African region is bleak. This recognition is tied to the idea of “getting to zero”, but is
punctuated by a nightmare scenario of not quite “getting to zero”, creating economic chaos and
“lost decades” to come and a perpetually “contaminated” region that diaspora and expatriate tourist
elements might flee from.
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